FBXO45

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FBXO45 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FBXO45 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FBXO45 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO45 expression acts as an unfavorable survival marker.

LIHC are the cancer types where FBXO45 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LIHCOSMedianAll0.0980.777<.00112view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FBXO45–LIHC (OS)

Kaplan–Meier survival curve for FBXO45 mutant vs wild-type samples in LIHC.

Open the LIHC breakdown →

Exploration